Israeli firm RedHill Biopharma has received the US Food and Drug Administration (FDA) approval to conduct a Phase IIa clinical trial of opaganib (Yeliva, ABC294640) to treat moderate-to-severe Covid-19.

Opaganib is an investigational, oral sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-inflammatory and anti-viral properties.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, double-blind, placebo-controlled Phase IIa trial will enrol up to 40 moderate-to-severe Covid-19 and pneumonia patients who require hospitalisation and supplemental oxygenation.

Participants will be given opaganib or placebo along with standard of care. The primary objective is the decrease in total oxygen requirement over the treatment duration for up to 14 days.

Secondary endpoints of the trial include time to 50% decrease in oxygen requirements, the proportion of patients without fever at day 14, and the proportion with negative nasal swabs at day 14.

RedHill Biopharma medical director Mark Levitt said: “There is a strong scientific rationale for the potential efficacy of opaganib in the treatment of Covid-19, including pre-clinical data demonstrating that opaganib may inhibit viral replication and reduce levels of IL-6 and TNF-alpha, important mediators of inflammation that are elevated in moderate-to-severe Covid-19 patients.

“This is coupled with encouraging preliminary data from the compassionate use programme in Israel, which demonstrated objective measurable clinical improvement in all six patients analysed, including a decrease in required supplemental oxygenation, higher lymphocyte counts, and decreased CRP levels.”

Preliminary data from six patients with moderate-to-severe Covid-19 who received opaganib under compassionate use in Israel have found significant measurable clinical improvement within days after treatment initiation with the drug.

All six patients were weaned from oxygen and discharged from the hospital. The drug was observed to be well-tolerated and demonstrated clinical improvement with and without hydroxychloroquine.